Blue Bees Therapeutics

Develops first-in-class immunotherapies based on a disruptive technology that exploits dual targeting of cellular receptors coupled to heparan sulfate proteoglycans (HSPG). This innovative approach aims to enhance the anti-tumor immune response and open up new therapeutic avenues.